A multicenter, single arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who have Hb>10 g/dL in response to anti-C5 antibody and switch and iptacopanadult PNH patients who have Hb >=10 g/dL in respo

Project: Research project

Project Details

Description

A multicenter, single arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who have Hb>10 g/dL in response to anti-C5 antibody and switch and iptacopanadult PNH patients who have Hb >=10 g/dL in respo
StatusActive
Effective start/end date1/14/23 → 2/3/26

Funding

  • NOVARTIS PHARMACEUTICALS CORPORATION

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
View full fingerprint